Home > Cardiology > AHA 2019 > Controversies in Contemporary Management of Aortic Stenosis > Full GALILEO results: Why did rivaroxaban fail after TAVR?

Full GALILEO results: Why did rivaroxaban fail after TAVR?

Presented By
Prof. George Dangas, Icahn School of Medicine at Mount Sinai, USA
Conference
AHA 2019
Trial
GALILEO

The full results of the prematurely terminated GALILEO trial confirm that oral anticoagulation with rivaroxaban was associated with worse clinical outcomes compared with antiplatelet therapy in patients after successful transcatheter aortic valve replacement (TAVR). However, the GALILEO-4D CT sub-study showed that rivaroxaban prevents some leaflet thickening and leaflet motion, indicative of a specific benefit. Both studies were simultaneously published in the New England Journal of Medicine [1,2].

Prof. George Dangas (Icahn School of Medicine at Mount Sinai, USA) pointed out that although current guidelines recommend dual antiplatelet therapy after TAVR, the evidence base for the optimal treatment strategy for patients who have had TAVR is weak [3]. Earlier observational studies provided some evidence that oral anticoagulati...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on